BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 03, 2008
 |  BioCentury  |  Finance

EPS watch

EPS watch

Company 3Q08 EPS est 3Q08 EPS actual Outcome Growth from 3Q07 10/31 cls Wk chg %chg Mcap chg 10/31 Mcap
AstraZeneca (LSE:AZN; NYSE:AZN) $1.14 $1.32 Beat by $0.18 27% $42.46 $5.95 16% $8,639.4 $61,651.9
3Q08 sales climbed 9% to $7.8B from $7.2B in the prior year's quarter. The company raised its FY08 Core EPS estimates to $4.90-$5.05 from $4.60-$4.90. Figures include a positive currency impact.
Bayer (Xetra:BAY) NA 0.37 NA -75% 43.16 1.71 4% $2,348.0 $42,390.9
3Q08 sales increased 2% to 7.9B ($11.9B) from 7.8B. Figures exclude a positive currency impact.
BioMarin (NASDAQ:BMRN; SWX:BMRN) $0.03 $0.01 Missed by $0.02 NA $18.32 $1.38 8% $137.6 $1,826.3

Read the full 946 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >